ARKG is trading at $49.62 (-3.46%) as pressure appears concentrated in growth-oriented holdings, not healthcare broadly. - Broader markets were higher; biotech had recently outperformed. - ARK’s reported November 2 trading activity showed notable reductions in Tempus AI, 10x Genomics, Intellia Therapeutics, and Recursion Pharmaceuticals. - Eli Lilly’s lowered adjusted EPS outlook was reported alongside ARK selling; these factors are consistent with pressure on ARKG but don’t establish a single definitive catalyst.